NETWORK PHARMACOLOGY STUDY ON THE MECHANISM OF DIABETIC NEUROPATHY TREATMENT USING MANGIFERIN

Tóm tắt

Mangiferin was the natural C-glycosyl xanthone compound with the various pharmacological activities, however, the absence of evidence for potential actions in diabetic neuropathy. Structure-based (molecular docking) and ligand-based (pharmacophore) methodologies, and network pharmacology could investigate the therapeutic potential of mangiferin for diabetic neuropathy due to simple and a system information of mechanism. Which structure-based methodologies, the diabetic neuropathy genes were determined by String db and converted to protein name with Uniprot. After mangiferin docking by Smina, the gene which coded the protein with the lower than -6 kcal/mol binding energy would be selected to the structure-based dataset. Also, the ligand-based dataset was composed of the genetics targets of mangiferin thought TargetNet and SwissTarget server. All gene belongs two datasets were the forces targets which further analyzed. Genemania and DAVID6.8 tools were used to obtain the GO and KEGG pathways. In results, 16 focus genes corresponding with 796 protein targets were revealed the mechanism of mangiferin in the diabetic neuropathy therapeutics. Furthermore, 91 biological processes and 29 pathways were disclosed according to the topological parameters of network pharmacology, specially, VEGF signaling pathway, HIF-1 signaling pathway, insulin resistance, and Alzheimer's disease. Mangiferin was suggested the good candidates for the diabetic uremic neuropathy and peripheral neuropathy onset and progression.